Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 5:12 PM
Ignite Modification Date: 2025-12-24 @ 5:12 PM
NCT ID: NCT05888350
Eligibility Criteria: Inclusion Criteria: 1. Age: 18-70 years; 2. Coughing lasting ≥ 8 weeks; 3. No abnormality in chest imaging in the past 3 months (or there is abnormality but the investigator judges it not the cause of chronic cough); 4. FEV1% pred\>70%;FEV1/FVC\>70%; 5. VAS≥30 in the past 48 hours; 6. Non-smokers or patients smoked less than 10 pack-years; 7. Candidates voluntarily participate in and abide by the relevant regulations of the study, can cooperate with corresponding inspections, follow the follow-up plan, and voluntarily sign written informed consent. Exclusion Criteria: 1. Patients received inhaled or oral corticosteroids or leukotriene receptor antagonist in previous 4 weeks; 2. Patients with history of upper respiratory tract infection in the past 8 weeks; 3. Patients taking angiotensin-converting enzyme inhibitors in previous 8 weeks; 4. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study; 5. Combined with a definite history of pulmonary diseases such as bronchiectasis, pulmonary interstitial disease, and pulmonary hypertension. Combined with other serious diseases (such as cardiovascular system diseases, metabolic system diseases, immune system diseases, nervous system diseases, etc.) that may affect the normal process of this study; 6. Participating in other drug clinical trial projects.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 70 Years
Study: NCT05888350
Study Brief:
Protocol Section: NCT05888350